Alira Health Welcomes Marie-Aude Ohresser, Vice President, Regulatory Affairs

News
Category:
Published on:
May 5, 2020

BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announces the appointment of Marie-Aude Ohresser to Vice President, Regulatory Affairs. Based in our Basel, Switzerland office, Marie-Aude will be instrumental in bolstering our EU regulatory capabilities as well as offering more comprehensive regulatory support globally.

Marie-Aude Ohresser

“We are delighted to welcome Marie-Aude to our Alira Health family. Marie-Aude joins us with a rich background and knowledge in the pharmaceutical industry including drug development, gene therapy, and various areas of regulatory affairs,” said Giacomo Basadonna, Chief Medical Officer, Alira Health. “Marie-Aude’s recruitment represents a fundamentally important step forward in expanding Alira Health’s global presence as a leading force in Regulatory Affairs for Pharma Products and Medical Devices, with the goal of transforming health care delivery for the benefit of patients around the world.”

“At this point in my career, I am ready for new challenges, and Alira Health is a perfect match for me. My new colleagues are dynamic, agile, and diligent and foster a supportive work environment,” said Marie-Aude. “I look forward to building on Alira Health’s existing pharma regulatory services as well as continuing to grow the synergies with our other divisions. I am confident that we are creating something extraordinary here, and the sky is the limit.”

Marie-Aude has over 20 years of experience in product development for the pharmaceutical industry. For the last decade, she worked with F. Hoffmann-La Roche, Ltd. as the Head of EU Liaison, Global Regulatory Affairs where she was responsible for planning and implementing strategy and activities such as optimizing resources and processes, developing KPIs, strengthening collaboration between affiliates and global regulatory departments to meet business needs. Marie-Aude has also led various cross-functional projects in the areas of regulatory records management and the pharmacovigilance system master file.

Most recently, Marie-Aude led changes related to Brexit across Roche’s pharmaceutical division. Prior to this, Marie-Aude was a regulatory strategist at Transgene SA and a project lead for a therapeutic vaccine in oncology. Marie-Aude has extensive knowledge of EU regulatory procedures and hands-on experience in preparing high-quality regulatory documentation.

To learn more about Marie-Aude, contact us.

Related news

Regulatory
Events July 20, 2021
Webinar Recap: Risk Management & Regulatory Submissions
Download Alira Health's Senior Vice President, Regulatory Affairs, Mary McNamara-Cullinane's webinar presentation, How to Implement Risk Management into Regulatory Submissions Using(...)
Regulatory
Publications July 20, 2021
Infographic: The Pre-IND to Market Approval Roadmap in the U.S.
Download our latest infographic, The Pre-IND to Market Approval Roadmap in the U.S.
Regulatory
Multimedia April 29, 2021
Alira Health Webinar Replay: Trends and Challenges in US and EU Combination Product Landscapes
Rewatch this timely webinar with Alira Health’s Regulatory leadership team featuring key insights and advice for U.S. and EU companies as they map out their own regulatory pathways(...)
Regulatory
News February 2, 2021
We Secured Breakthrough Device Designation from FDA on PEDRA Xauron Perfusion System
We are proud to announce the firm’s Regulatory practice has secured a Breakthrough Device Designation from FDA for the real-time tissue perfusion system, PEDRA Xauron Perfusion System.
Clinical Regulatory
News January 7, 2021
Alira Health Adds CMC Services through Acquisition of Chamow & Associates
We have acquired Chamow & Associates (www.chamowassociates.com), a California-based integrated CMC advisory firm. This acquisition brings expertise in biologics manufacturing, quality(...)
Advanced Analytics Regulatory Research & Development
News November 20, 2020
Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round
Alira Health congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device toward clinical trials.(...)
Regulatory
Publications November 1, 2020
Reduce Time to Market with Pre-IND Meetings
Did you know reducing time to market is one of the biggest challenges companies face when seeking FDA approval on their drug development plans and clinical trials?

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.